“At the upcoming ASH meeting, updated clinical data will be presented
regarding NK-92 therapy,” said
Details of the presentation are listed below and available on the ASH website:
- Title: “NK-92 Therapy Is Well Tolerated, Has Minimal Toxicity and Shows Efficacy in a Phase I Trial of Patients with Relapsed/Refractory Hematological Malignancies Relapsing after Autologous Stem Cell Transplantation.”
Monday, December 7, 2015from 6 p.m.-8 p.m.in Hall A of the Orange County Convention Center.
Brent Williams BSc(Hon), BSc(Med), MD, PhD, FRCP(C), FAAP Associate Staff, Division of Emergency Medicine The Hospital for Sick Children Research Associate, Cell Therapy Program, Princess Margaret Cancer Centre.
- Session: 703 Adoptive Immunotherapy: Poster III.
The abstract will also be published online in the
NK-92 are natural killer (NK) cells and the only cell line that can be commercialized as a direct, scalable, off-the-shelf product that attacks and kills abnormal cells on contact. Unlike other immunotherapies, NK-92 does not require an intact immune system to effect killing of diseased cells in the body. It has demonstrated broad anti-cancer activity both in vitro and in clinical trials, while sparing patients from debilitating adverse reactions seen commonly with traditional chemotherapies. NK-92 cells are also being engineered to target specific cancers and also to express a receptor that will couple with monoclonal antibodies to enhance their cancer-killing effects.
NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3) Targeted activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious "cytokine storms"
reported after T cell therapy. As an “off-the-shelf” therapy,
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe
This news release contains certain statements of a forward-looking
nature relating to future events or future business performance. Any
such statements, including, but not limited to, the success and timing
of our clinical trials and preclinical studies for our product
candidates, whether expressed or implied, are subject to risks and
uncertainties which can cause actual results to differ materially from
those currently anticipated due to a number of factors which include,
but are not limited to, including site initiation, internal review board
approval, scientific review committee approval, patient accrual, safety,
tolerability and efficacy data observed, and input from regulatory
authorities; our plans to develop and commercialize our product
candidates; our available cash and investments; our ability to obtain
and maintain intellectual property protection for our product
candidates; our ability to manufacture; the performance of third-party
manufacturers, clinical research organizations, clinical trial sponsors
and clinical trial investigators, and other risk factors discussed in
the company's Form 10-K and other documents filed with the